Study of Tissue and Blood Samples From Patients With High-Grade Glioma
Study of Tissue and Blood Samples From Patients With High-Grade Glioma
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the
 laboratory may help doctors learn more about changes that occur in DNA and identify
 biomarkers related to cancer. It may also help doctors predict how patients will respond to
 treatment.

 PURPOSE: This research study is looking at tissue and blood samples from patients with
 high-grade glioma.
OBJECTIVES:

 -  To evaluate the diagnostic and prognostic relevance of various molecular, cytogenetic,
 and other tumor markers in high-grade glioma in paraffin-embedded tissue collected from
 patients enrolled in the Mayo Clinic or North Central Cancer Treatment Group (NCCTG)
 high-grade glioma trials conducted since 1979.

 -  To evaluate alterations of specific chromosomes and chromosomal regions including 7, 9p,
 10p, 10q, 13q, 17p, 17q, 19q, 22q, X, and Y using PCR analysis of microsatellite repeats
 and FISH.

 -  To determine DNA ploidy by flow cytometric analysis.

 -  To examine various markers of cellular proliferation and cellular function including
 flow cytometric determination of %S-phase, %G2M, and immunohistochemical evaluation of
 PCNA, Ki-67, and p53.

 -  To evaluate additional markers identified by the Glioma Markers Network.

 -  To compare the incidence of markers in the major histologic subtypes (anaplastic
 astrocytoma [AA], anaplastic oligoastrocytoma [AOA], glioblastoma multiforme [GBM]) and
 to assess their correlation in the total group, as well as within each of these
 subtypes.

 -  To compare the ploidy determinations by FISH and flow cytometry.

 OUTLINE: Paraffin-embedded tissue and peripheral blood samples, previously or currently
 collected from clinical trials participants at the time she/he enrolled in the trial, are
 evaluated for as many markers as possible, changes in cytogenic and molecular genetic tumor
 markers, frequency distributions of all tumor markers and histological and clinical variables
 by polymerase chain reaction, IHC, flow cytometry, and FISH analysis.
-  Patients with newly diagnosed high-grade gliomas

 -  Patients participating in NCCTG/Alliance or Mayo protocols

 -  Willing to provide mandatory blood and tissue samples for research purposes; note: 15
 unstained slides may be submitted in place of a tissue block